Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level

被引：3

作者：

Bazhenova, L. ^{[1
]}

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷 / 04期

关键词：

1ST-LINE NIVOLUMAB; PLUS IPILIMUMAB; ADENOCARCINOMA; CHEMOTHERAPY; EFFICACY; SENSITIVITY; ASSOCIATION; OUTCOMES; NSCLC;

D O I：

10.1016/j.annonc.2023.02.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：6

共 32 条

[1]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[2] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[3] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].

Chalmers, Zachary R. ;

Connelly, Caitlin F. ;

Fabrizio, David ;

Gay, Laurie ;

Ali, Siraj M. ;

Ennis, Riley ;

Schrock, Alexa ;

Campbell, Brittany ;

Shlien, Adam ;

Chmielecki, Juliann ;

Huang, Franklin ;

He, Yuting ;

Sun, James ;

Tabori, Uri ;

Kennedy, Mark ;

Lieber, Daniel S. ;

Roels, Steven ;

White, Jared ;

Otto, Geoffrey A. ;

Ross, Jeffrey S. ;

Garraway, Levi ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Frampton, Garrett M. .

GENOME MEDICINE, 2017, 9

[4] Durvalumab (D) ± tremelimumab (T) plus chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y) [J].

Cho, B. C. ;

Luft, A. ;

Alexander, J. A. Alatorre ;

Geater, S. Lucien ;

Laktionov, K. ;

Sang-We, K. ;

Ursol, G. ;

Hussein, M. ;

Farah, L. Lim ;

Yang, C. T. ;

Araujo, L. H. ;

Saito, H. ;

Reinmuth, N. ;

Lai, Z. ;

Mann, H. ;

Shi, X. ;

Peters, S. ;

Garon, E. B. ;

Mok, T. S. K. ;

Johnson, M. L. .

ANNALS OF ONCOLOGY, 2022, 33 :S1569-S1570

[5] Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [J].

Garassino, Marina C. ;

Gadgeel, Shirish ;

Novello, Silvia ;

Halmos, Balazs ;

Felip, Enriqueta ;

Speranza, Giovanna ;

Hui, Rina ;

Garon, Edward B. ;

Horinouchi, Hidehito ;

Sugawara, Shunichi ;

Rodriguez-Abreu, Delvys ;

Reck, Martin ;

Cristescu, Razvan ;

Aurora-Garg, Deepti ;

Loboda, Andrey ;

Lunceford, Jared ;

Kobie, Julie ;

Ayers, Mark ;

Piperdi, Bilal ;

Pietanza, M. Catherine ;

Paz-Ares, Luis .

JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (01)

[6] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].

Hellmann, M. D. ;

Paz-Ares, L. ;

Bernabe Caro, R. ;

Zurawski, B. ;

Kim, S. -W. ;

Carcereny Costa, E. ;

Park, K. ;

Alexandru, A. ;

Lupinacci, L. ;

de la Mora Jimenez, E. ;

Sakai, H. ;

Albert, I. ;

Vergnenegre, A. ;

Peters, S. ;

Syrigos, K. ;

Barlesi, F. ;

Reck, M. ;

Borghaei, H. ;

Brahmer, J. R. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Rabindran, S. K. ;

Kasinathan, R. S. ;

Nathan, F. E. ;

Ramalingam, S. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031

[7] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[8]

Herbst RS, 2019, ANN ONCOL, V30, P916

[9] Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer [J].

Hong, Lingzhi ;

Aminu, Muhammad ;

Li, Shenduo ;

Lu, Xuetao ;

Petranovic, Milena ;

Saad, Maliazurina B. ;

Chen, Pingjun ;

Qin, Kang ;

Varghese, Susan ;

Rinsurongkawong, Waree ;

Rinsurongkawong, Vadeerat ;

Spelman, Amy ;

Elamin, Yasir Y. ;

Negrao, Marcelo V. ;

Skoulidis, Ferdinandos ;

Gay, Carl M. ;

Cascone, Tina ;

Gandhi, Saumil J. ;

Lin, Steven H. ;

Lee, Percy P. ;

Carter, Brett W. ;

Wu, Carol C. ;

Antonoff, Mara B. ;

Sepesi, Boris ;

Lewis, Jeff ;

Gibbons, Don L. ;

Vaporciyan, Ara A. ;

Le, Xiuning ;

Jack Lee, J. ;

Roy-Chowdhuri, Sinchita ;

Routbort, Mark J. ;

Gainor, Justin F. ;

Heymach, John V. ;

Lou, Yanyan ;

Wu, Jia ;

Zhang, Jianjun ;

Vokes, Natalie I. .

NATURE COMMUNICATIONS, 2023, 14 (01)

[10] Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome [J].

Ihle, Nathan T. ;

Byers, Lauren A. ;

Kim, Edward S. ;

Saintigny, Pierre ;

Lee, J. Jack ;

Blumenschein, George R. ;

Tsao, Anne ;

Liu, Suyu ;

Larsen, Jill E. ;

Wang, Jing ;

Diao, Lixia ;

Coombes, Kevin R. ;

Chen, Lu ;

Zhang, Shuxing ;

Abdelmelek, Mena F. ;

Tang, Ximing ;

Papadimitrakopoulou, Vassiliki ;

Minna, John D. ;

Lippman, Scott M. ;

Hong, Waun K. ;

Herbst, Roy S. ;

Wistuba, Ignacio I. ;

Heymach, John V. ;

Powis, Garth .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (03) :228-239

← 1 2 3 4 →